Burosumab, a fully humanized FGF23-antibody, was recently approved for treatment of X-linked hypophosphatemia (XLH) and TIO and shown to be superior for treatment of XLH compared to conventional treatment. This evidence concerns the gene FGF23 and X-linked dominant hypophosphatemic rickets.